mRNA Melanoma Vaccine Cuts Recurrence Risk 42% in Trial

A personalized cancer therapy built on mRNA, the technology Moderna is best known for, has produced one of the most closely watched results in oncology this year. On Oct. 22, 2026, Merck and Moderna reported that their investigational therapy intismeran autogene (also called V940 or mRNA-4157), given alongside Merck's immunotherapy Keytruda (pembrolizumab), cut the risk of melanoma returning or death by 42% in a large Phase 3 trial. The data were scheduled for presentation at the European Society for Medical Oncology (ESMO) congress in Madrid on Oct. 24, and the trial ran at 157 centers, Nature reported.

Health information, not medical advice. This article summarizes trial results reported by the companies and independent coverage. Talk with a doctor about any treatment decision.

Melanoma vaccine trial results: what INTerpath-001 found

According to Merck's announcement, INTerpath-001 is a randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov NCT05933577) in 1,137 adults with high-risk stage IIB to IV cutaneous melanoma that had been completely removed by surgery. Patients were assigned 2-to-1 to intismeran plus Keytruda or placebo plus Keytruda for about a year.

Source: Merck press release, Oct. 22, 2026.

How to read a hazard ratio: a hazard ratio of 0.58 means that, over the follow-up period, patients on the combination had their cancer return (or died) at about 58% of the rate seen with Keytruda alone, which is where the "42% lower risk" figure comes from.

The benefit appeared after six months

One detail stood out to researchers. In the first six months, while patients were still receiving the vaccine doses, results in the two groups were about the same. After that point, a pre-specified analysis showed the combination cut the risk of recurrence or death by 58% compared with Keytruda alone, Merck said. That pattern fits the idea that the therapy needs time to train the immune system.

What it is and is not

Intismeran is not a preventive vaccine. As Nature explains, it is designed to stop melanoma from coming back in people who have already had tumors removed. To make each dose, researchers sequence DNA from a patient's tumor and from healthy tissue, identify mutations unique to the cancer and build an mRNA molecule that codes for up to 34 of those "neoantigens", according to Merck. Once injected, the instructions prompt the body to display those cancer-specific markers so T cells can recognize and attack cancer cells.

What we don't know yet

• Survival. Merck said overall survival data are "not yet mature," though a favorable trend has been observed. The study continues, and trial leader Georgina Long of Melanoma Institute Australia told Nature that patients will be followed for several years.
• Long-term durability. Cancer geneticist Jessamy Tiffen of Sydney's Centenary Institute told Nature the results are exciting but "only time will tell" how effective the treatment is beyond two years, and noted that some patients did not respond.
• Who benefits most. Long said her team will run analyses to identify which patients are most likely to benefit. Results were "generally consistent" across pre-specified subgroups, per Merck.

Side effects

Treatment-related side effects of any grade were common in both groups: 95.8% with the combination and 90.0% with Keytruda alone. Serious (grade 3 to 5) side effects were similar, at 14.2% versus 13.4%. The most common side effects with the combination were fever (52.2%), injection-site pain (51.0%) and fatigue (38.5%). The companies said no new safety signals were seen.

Why this story is trending

Melanoma is one of the deadliest forms of skin cancer and accounts for most skin cancer deaths in the U.S., according to Merck's release, which cites estimates of about 112,000 new U.S. cases and more than 8,500 deaths in 2026. Experts quoted by Nature called the size of the effect remarkable: a risk reduction of 10% is regarded as substantial in oncology, one immunotherapy researcher said. The story also moved markets. Nature reported that the key data leaked online on Oct. 22, prompting the early release, and that Moderna's stock fell about 25% after the leak, which one analyst attributed to inflated expectations rather than doubts about efficacy. Moderna's shares and its ticker, MRNA, appeared among U.S. Google search trends the same day.

What's next

1. Regulators. Merck said that "based on these data, we are engaging with regulatory authorities." No application timeline or approval date has been announced.
2. Publication. The results have been accepted for publication in The New England Journal of Medicine, according to Merck.
3. Other cancers. The INTerpath program includes nine Phase 2 and Phase 3 trials, including three Phase 3 trials in non-small cell lung cancer, with smaller studies in pancreatic and gastric cancers.

If you or a family member has melanoma

The therapy is available only in clinical trials. The National Cancer Institute's melanoma treatment overview explains current, approved options, and ClinicalTrials.gov lists studies along with their recruiting status. Your oncologist can tell you whether any trial fits your situation.

Two big questions are still open: whether intismeran helps people live longer, and whether the benefit holds up past two years. Until those answers arrive, and until regulators weigh in, this is a striking trial result, not a treatment your doctor can prescribe.

Other stories we're following this week: the toothpaste recall affecting kids' brands and the record Four Corners flooding.